Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.

Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, London WB, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaau1099. doi: 10.1126/scitranslmed.aau1099.

PMID:
30700572
2.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.

PMID:
30545920
3.

Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.

Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI.

Eur J Cancer. 2017 Sep;83:132-141. doi: 10.1016/j.ejca.2017.06.024. Epub 2017 Jul 20.

4.

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.

Evageliou NF, Haber M, Vu A, Laetsch TW, Murray J, Gamble LD, Cheng NC, Liu K, Reese M, Corrigan KA, Ziegler DS, Webber H, Hayes CS, Pawel B, Marshall GM, Zhao H, Gilmour SK, Norris MD, Hogarty MD.

Clin Cancer Res. 2016 Sep 1;22(17):4391-404. doi: 10.1158/1078-0432.CCR-15-2539. Epub 2016 Mar 24.

5.

Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.

Gamble LD, Hogarty MD, Liu X, Ziegler DS, Marshall G, Norris MD, Haber M.

Front Oncol. 2012 Nov 16;2:162. doi: 10.3389/fonc.2012.00162. eCollection 2012.

6.

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA.

Cell Cycle. 2011 Nov 1;10(21):3778-87. doi: 10.4161/cc.10.21.17973. Epub 2011 Nov 1.

PMID:
22052359
7.

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Gamble LD, Kees UR, Tweddle DA, Lunec J.

Oncogene. 2012 Feb 9;31(6):752-63. doi: 10.1038/onc.2011.270. Epub 2011 Jul 4.

8.

p53 is a direct transcriptional target of MYCN in neuroblastoma.

Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.

Cancer Res. 2010 Feb 15;70(4):1377-88. doi: 10.1158/0008-5472.CAN-09-2598. Epub 2010 Feb 9.

Supplemental Content

Loading ...
Support Center